Regulatory, Business, Transactional & Litigation Counsel for Businesses Across the Peptide & GLP-1 Ecosystem
The peptides and GLP-1 marketplace is transforming healthcare, life sciences, wellness, and digital health. From emerging peptide-based companies and telehealth models to compounded GLP-1 products, the legal landscape continues to shift as FDA, state boards of pharmacy, FTC, and private litigants increase scrutiny across the industry.
Frier Levitt has built one of the nation’s most comprehensive legal practices dedicated to serving the peptide and GLP-1 industry.
Frier Levitt represents businesses across the peptide and GLP-1 ecosystem, providing integrated regulatory, transactional, litigation, and business counsel nationwide. Our multidisciplinary team includes scientifically trained FDA regulatory attorneys, pharmacist attorneys, healthcare regulatory counsel, corporate and transactional attorneys, and experienced litigators. By bringing these disciplines together under one roof, we help clients navigate not only the complex regulatory landscape, but also the scientific, operational, and commercial realities unique to this rapidly evolving industry.
Whether launching a new peptide venture, developing a telehealth platform, manufacturing compounded GLP-1 products, expanding a wellness business, responding to an FDA inquiry, raising capital, or preparing for acquisition, we provide practical, business-focused legal strategies designed to help companies grow while managing regulatory risk.
Why Frier Levitt
Frier Levitt brings together attorneys with experience across FDA regulation, pharmacy law, healthcare compliance, corporate transactions, litigation, and life sciences. This multidisciplinary approach allows us to advise clients throughout the entire business lifecycle, from startup formation and product launch to commercial growth, investment, enforcement defense, and strategic transactions.
We represent clients across the entire peptide and GLP-1 ecosystem, including:
- Innovative ventures and startups
- Peptide manufacturers and distributors
- Active pharmaceutical ingredient (API) manufacturers
- Importers and distributors
- 503A compounding pharmacies
- 503B outsourcing facilities
- Telehealth platforms
- Med spas
- Wellness clinics
- Physicians and healthcare providers
- Prescribers
- Investors
- Technology companies serving the healthcare and life sciences industries
Our attorneys actively monitor ongoing regulatory developments affecting the industry, including FDA enforcement trends, evolving compounding restrictions, and advertising scrutiny. We actively track FDA Warning Letters, criminal enforcement actions, Pharmacy Compounding Advisory Committee (PCAC) proceedings, interim bulk drug substance list updates, and evolving “intended use” guidance. We translate these developments into practical, forward-looking guidance that helps clients anticipate regulatory change rather than simply react to it.
Regulatory Advisory Services
We advise clients on a wide range of peptide and GLP-1 regulatory matters, including:
- FDA regulatory compliance and enforcement preparedness
- Compounding compliance under Sections 503A and 503B
- “Essentially a copy” analyses for compounding of branded drugs
- FTC advertising and promotion compliance review
- Import compliance
- CBP seizures and international trade matters
- Product classification and jurisdictional analyses
- Telehealth and prescribing compliance
- State board of pharmacy and board of medicine compliance
- FDA product label compliance
- Manufacturing and distribution agreements
- Supply chain and sourcing transactions
- Corporate practice of medicine issues
- Pharmacy inspections and enforcement preparedness
- FDA warning letters, investigations, and enforcement defense
- State Law compliance
We also advise businesses on the operational realities of evolving FDA enforcement priorities and changing regulatory interpretations impacting peptides and compounded GLP-1 products.
Transactions, Growth, and Strategic Counsel
Building a successful peptide business requires more than regulatory compliance. We help businesses build scalable legal frameworks that support growth while minimizing regulatory exposure.
Our transactional services include:
- Business formation
- Entity and ownership arrangements
- MSOs and management structures
- Vendor and supplier agreements
- Telehealth platform agreements
- Professional services agreements
- Investment and financing transactions
- Intellectual property and licensing matters
- Mergers, acquisitions, and strategic partnerships
- Due diligence and regulatory risk assessments
Our multidisciplinary approach allows us to support clients through every stage of growth, from startup formation and product launch to expansion, investment, and M&A exits.
Litigation, Investigations and Enforcement Defense
As scrutiny in the peptide and GLP-1 market continues to increase, companies face growing risks from regulators, competitors, consumers, and private plaintiffs.
Our team represents clients in matters involving:
- FDA and FTC enforcement actions
- State regulatory investigations
- False advertising disputes
- Competitor and unfair competition claims
- Trademark and branding disputes
- Commercial litigation
- Consumer class action risks
- Contract disputes
- Pharmacy and healthcare enforcement matters
Whenever possible, we work proactively to identify and mitigate legal risks before disputes arise while remaining prepared to defend clients when enforcement or litigation occurs.
Industry Leadership
Frier Levitt attorneys regularly publish articles and legal analyses addressing the most significant developments affecting the peptide and GLP-1 marketplace, including FDA enforcement trends, compounding regulation, telehealth compliance, FTC advertising enforcement, FDA guidance, bulk drug substances, and emerging regulatory policy.
Our attorneys are frequent speakers at national conferences and have been featured in leading publications, including The Wall Street Journal, Financial Times, The Hill, and other respected healthcare and life sciences media outlets. Through our ongoing thought leadership, we help businesses understand not only current legal requirements but also the regulatory trends likely to shape the industry’s future.
How Frier Levitt Can Help
Scientific innovation, evolving regulation, increased enforcement, and significant investment continue to reshape the peptide and GLP-1 marketplace. Businesses operating in this space require legal counsel that understands not only FDA and healthcare law, but also the commercial realities driving one of the fastest-growing sectors in healthcare.
Whether you are launching a peptide company, operating a telehealth platform, manufacturing compounded GLP-1 products, expanding a wellness business, responding to an FDA inquiry, evaluating an investment opportunity, or preparing for a strategic transaction, Frier Levitt provides integrated legal counsel designed to help businesses navigate risk, seize opportunity, and achieve sustainable, long-term growth. Contact our team today to learn how we can help you.